Identification of genes differentially expressed between benign and osteopontin transformed rat mammary epithelial cells

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Kurisetty, Vittal V ^a   Johnston, Patrick G ^a   Rudland, Philip S ^b   El Tanani, Mohamed K ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA TELANGIECTASIA; RATTUS;

EID: 77049108907     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-15     Document Type: Article

References (27)

1. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. VV Kurisetty PG Johnston N Johnston P Erwin P Crowe DG Fernig FC Campbell IP Anderson PS Rudland MK El-Tanani, Oncogene 2008 27 57 7139 7149 10.1038/onc.2008.325 18794800
2. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. EI Behrend AM Craig SM Wilson DT Denhardt AF Chambers, Cancer Res 1994 54 3 832 837 8306346
3. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. N Euer M Schwirzke V Evtimova H Burtscher M Jarsch D Tarin UH Weidle, Anticancer Res 2002 22 2A 733 740 12014644
4. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. AB Tuck C Hota AF Chambers, Breast Cancer Res Treat 2001 70 3 197 204 10.1023/A:1013095329825 11804183
5. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. AJ Oates R Barraclough PS Rudland, Oncogene 1996 13 1 97 104 8700559 (Pubitemid 26248549)
6. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. PS Rudland A Platt-Higgins C Renshaw CR West JH Winstanley L Robertson R Barraclough, Cancer Res 2000 60 6 1595 1603 10749128 (Pubitemid 30183430)
7. Osteopontin expression in a group of lymph node negative breast cancer patients. AB Tuck FP O'Malley H Singhal JF Harris KS Tonkin N Kerkvliet Z Saad GS Doig AF Chambers, Int J Cancer 1998 79 5 502 508 10.1002/(SICI)1097- 0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3 9761120
8. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. PS Rudland A Platt-Higgins M El-Tanani S De Silva Rudland R Barraclough JH Winstanley R Howitt CR West, Cancer Res 2002 62 12 3417 3427 12067984
9. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. H Singhal DS Bautista KS Tonkin FP O'Malley AB Tuck AF Chambers JF Harris, Clin Cancer Res 1997 3 4 605 611 9815727
10. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. L Diatchenko YF Lau AP Campbell A Chenchik F Moqadam B Huang S Lukyanov K Lukyanov N Gurskaya ED Sverdlov PD Siebert, Proc Natl Acad Sci USA 1996 93 12 6025 6030 8650213 10.1073/pnas.93.12.6025 (Pubitemid 26190796)
11. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. M El-Tanani R Barraclough MC Wilkinson PS Rudland, Cancer Res 2001 61 14 5619 5629 11454716
12. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. R Fenrick L Wang J Nip JM Amann RJ Rooney J Walker-Daniels HC Crawford DL Hulboy MS Kinch LM Matrisian SW Hiebert, Mol Cell Biol 2000 20 16 5828 5839 10913166 10.1128/MCB.20.16.5828-5839.2000 (Pubitemid 30613032)
13. BRCA1 Suppresses Osteopontin-mediated Breast Cancer. MK El-Tanani FC Campbell P Crowe P Erwin DP Harkin P Pharoah B Ponder PS Rudland, J Biol Chem 2006 281 36 26587 26601 10.1074/jbc.M604403200 16807234
14. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. M Tuynder L Susini S Prieur S Besse G Fiucci R Amson A Telerman, Proc Natl Acad Sci USA 2002 99 23 14976 14981 12399545 10.1073/pnas.222470799 (Pubitemid 35334595)
15. Prognostic significance of endothelial Per-Arnt-sim domain protein 1/hypoxia-inducible factor-2alpha expression in a subset of tumor associated macrophages in invasive bladder cancer. F Koga Y Kageyama S Kawakami Y Fujii N Hyochi N Ando T Takizawa K Saito A Iwai H Masuda K Kihara, J Urol 2004 171 3 1080 1084 10.1097/01.ju.0000110541.62972.08 14767275
16. Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-fms in mammary glands of transgenic mice results in hyperplasia and tumor formation. N Kirma R Luthra J Jones YG Liu HB Nair U Mandava RR Tekmal, Cancer Res 2004 64 12 4162 4170 10.1158/0008-5472.CAN-03-2971 15205327
17. Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. SA Murray S Yang E Demicco H Ying DH Sherr LJ Hafer AE Rogers GE Sonenshein ZX Xiao, J Cell Biochem 2005 95 5 875 884 10.1002/jcb.20414 15844214
18. The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. L Udabage GR Brownlee SK Nilsson TJ Brown, Exp Cell Res 2005 310 1 205 217 10.1016/j.yexcr.2005.07.026 16125700
19. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. YC Su MT Wu CJ Huang MF Hou SF Yang CY Chai H Kang G Watkins A Douglas-Jones RE Mansel WG Jiang, Breast 2005 14 5 360 367 10.1016/j.breast.2004.12.007 16216737
20. Gene expression profiling in the mammary gland of rats treated with 7,12-dimethylbenz[a]anthracene. AD Papaconstantinou I Shanmugam L Shan IS Schroeder C Qiu M Yu EG Snyderwine, Int J Cancer 2005 118 1 17 24 10.1002/ijc.21247
21. Clinical significance of bone marrow micrometastases of breast tumors. S Dubecz Jr O Csuka K Torok N Vasas G Peley Z Doleschal Z Sulyok I Lang I Koves, Magy Seb 2003 56 3-4 108 112 14619093
22. Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens. PS Crusius CM Forcelini AB Mallmann DA Silveira E Lersch CA Seibert MU Crusius CA Carazzo CU Crusius E Goellner, Arq Neuropsiquiatr 2005 63 3b 864 869 16258673
23. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. DJ Freeman AG Li G Wei HH Li N Kertesz R Lesche AD Whale H Martinez-Diaz N Rozengurt RD Cardiff X Liu H Wu, Cancer Cell 2003 3 2 117 130 10.1016/S1535-6108(03)00021-7 12620407
24. Tumor suppressor genes and breast cancer. TA Buchholz MM Weil MD Story EA Strom WA Brock MD McNeese, Radiat Oncol Investig 1999 7 2 55 65 10.1002/(SICI)1520-6823(1999)7:2<55::AID-ROI1>3.0.CO;2-# 10333246
25. 5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. JS Nam Y Ino Y Kanai M Sakamoto S Hirohashi, Clin Exp Metastasis 2004 21 1 49 56 10.1023/B:CLIN.0000017180.19881.c1 15065602
26. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. F Ponchel C Toomes K Bransfield FT Leong SH Douglas SL Field SM Bell V Combaret A Puisieux AJ Mighell PA Robinson CF Inglehearn JD Isaacs AF Markham, BMC Biotechnol 2003 3 18 14552656 10.1186/1472-6750-3-18 (Pubitemid 38846458)
27. Identification of mRNAs differentially-expressed between benign and malignant breast tumour cells. D Liu PS Rudland DR Sibson R Barraclough, Br J Cancer 2002 87 4 423 431 10.1038/sj.bjc.6600456 12177779